A Director at VistaGen Therapeutics (NASDAQ: VTGN) is Buying Shares

By Carrie Williams

Today, a Director at VistaGen Therapeutics (VTGNResearch Report), Jon Saxe, bought shares of VTGN for $25.16K.

In addition to Jon Saxe, one other VTGN executive reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

The Company has a Price to Book ratio of 23.2816. Currently, VistaGen Therapeutics has an average volume of 264.9K.

Starting in May 2018, VTGN received 19 Buy ratings in a row.

Jon Saxe’s trades have generated a 5.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.